Observational follow up study of ENEST1st.

• Research type

  Research Study

• Full title

  An observational, open-label, multi-center, prospective follow-up study of patients with chronic phase CML treated with nilotinib in the ENEST1st (CAMN107EIC01) study.

• IRAS ID

  118744

• Contact name

  Dragana Milojkovic

• Contact email

  d.milojkovic@imperial.ac.uk

• Sponsor organisation

  Novartis Oncology Region Europe

• REC name

  South Central - Oxford C Research Ethics Committee

• REC reference

  13/SC/0063

• Date of REC Opinion

  24 Jan 2013

• REC opinion

  Favourable Opinion